In:
Alimentary Pharmacology & Therapeutics, Wiley, Vol. 55, No. 4 ( 2022-02), p. 434-445
Abstract:
Data are limited regarding the risk of hepatitis C virus (HCV) reinfection after treatment‐induced sustained virologic response (SVR) in patients on haemodialysis. Aims To assess the risk of HCV reinfection among patients on haemodialysis with treatment‐induced SVR. Methods Patients on haemodialysis patients who achieved SVR 12 with interferon (IFN) or direct‐acting antiviral (DAA)‐based treatment received follow‐up at SVR 24 and then biannually with HCV RNA measurements. HCV reinfection was defined as the resurgence of viremia by different viral strains beyond SVR 12 . The low‐risk general population who achieved SVR 12 and who underwent the same post‐SVR 12 surveillance served as the reference group. Crude reinfection rates per 100 person‐years (PYs) were calculated. Multivariate Cox regression analysis was performed to estimate the relative risk of HCV reinfection between the two groups. Results We recruited 374 patients on haemodialysis and 1571 reference patients with a mean post‐SVR 12 follow‐up of 4.7 and 6.1 years. All haemodialysis patients who achieved SVR 12 also achieved SVR 24 . The incidence rates of HCV reinfection were 0.23 per 100 PYs (95% confidence interval [CI]: 0.09‐0.59) in haemodialysis patients and 0.16 per 100 PYs (95% CI: 0.10‐0.26) in the reference group. The risk of HCV reinfection in patients on haemodialysis was comparable to that in the reference patients (hazard ratio [HR] : 1.39; 95% CI: 0.44‐4.38, P = 0.57). Conclusions The risk of HCV reinfection in patients on haemodialysis who achieve SVR 12 is low and comparable to that in the low‐risk general population. HCV microelimination in this special population is feasible once universal screening and scaled‐up treatment are implemented.
Type of Medium:
Online Resource
ISSN:
0269-2813
,
1365-2036
Language:
English
Publisher:
Wiley
Publication Date:
2022
detail.hit.zdb_id:
2003094-0
SSG:
15,3